October 21, 2014

Elyria
Cloudy
52°F
test

Invacare making progress in FDA review of Elyria facility

NEW YORK — Shares of Invacare Corp. advanced Tuesday after the company said it is making progress in a government review of its Elyria facility. The FDA had limited production at the plant because of manufacturing problems.

Invacare, which makes wheelchairs, crutches and motorized scooters, said late Monday that the Food and Drug Administration accepted the results of the first audit of the Elyria manufacturing facility. That means the facility can resume manufacturing and distributing parts to other Invacare plants.

Two other audits need to be completed before the facility can resume full operations.

The FDA said in December that Invacare had agreed to stop making, designing and distributing manual and powered wheelchairs and wheelchair parts at two facilities because of violations of quality systems regulations and failures to properly report problems to the agency.

Production would be limited until inspectors certify that the company is in compliance with FDA regulations.

Invacare stock rose $1.21, or 8.9 percent, to close at $14.87. Shares have dropped 8.8 percent in 2013.